SBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Draft Letter of Offer to the Public Shareholders of Bliss GVS Pharma Ltd ("Target Company").
M&A
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 09 Jun 2026, 10:19 AM IST · BSE ID: f9937aed-ae0b-4de3-90d2-a411a936de12
View Original BSE Filing (PDF)
💡
In Simple Terms
Anupam Rasayan India is making a cash offer to buy 26.00% of Bliss GVS Pharma shares from public shareholders at ₹ 299.00 each.
🤖 AI Summary
- SBI Capital Markets Ltd submitted Draft Letter of Offer for Anupam Rasayan India's open offer.
- Offer is to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Ltd.
- This represents 26.00% of Bliss GVS Pharma's Expanded Voting Share Capital.
- The cash offer price is ₹ 299.00 per equity share for public shareholders.
- Offer is compliant with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Number of Equity Shares to be acquired
2,77,26,848
Percentage of Expanded Voting Share Capital
26.00%
Offer Price per Equity Share
₹ 299.00
🏢 How This Affects the Company
This open offer could result in a significant change in the ownership structure and strategic direction of Bliss GVS Pharma Ltd, depending on the outcome of the acquisition.
The acquisition of 26.00% of shares by Anupam Rasayan India Limited will transfer cash consideration of ₹ 299.00 per share to tendering public shareholders.
The open offer process introduces regulatory scrutiny and potential for changes in company control, which are inherent risks in such transactions.
👥 What This Means For Shareholders
✅
Action Required
Eligible public shareholders of Bliss GVS Pharma Limited wishing to tender their shares must review the Letter of Offer and submit the Form of Acceptance-cum-Acknowledgement during the tendering period.
👤
Who Is Affected
Public shareholders holding up to 2,77,26,848 fully paid-up equity shares of Bliss GVS Pharma Limited are affected, as they can tender their shares at ₹ 299.00 each.
🔍
Management Signal
The filing indicates the ongoing regulatory process to facilitate Anupam Rasayan India's attempt to acquire a significant stake in Bliss GVS Pharma.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
SEBI approval of the Draft Letter of Offer.
Announcement of the final Letter of Offer and open offer schedule.
Public announcement of the results and settlement of the open offer.
MEDIUM RISK
The open offer's success and full impact depend on shareholder participation and regulatory clearances, carrying execution risk.
💡 Investor Takeaway
Anupam Rasayan India Limited has moved forward with its open offer for Bliss GVS Pharma Ltd, submitting the Draft Letter of Offer dated June 08, 2026. This confirms the cash offer to acquire up to 2,77,26,848 equity shares, representing 26.00% of the Expanded Voting Share Capital, at ₹ 299.00 per equity share.
⚖️ Strengths & Concerns
✅ Positives
- The open offer provides public shareholders with an opportunity to exit their holdings at a specified price of ₹ 299.00 per equity share.
- The offer is a clear, non-conditional cash offer for 26.00% of the company's Expanded Voting Share Capital, in compliance with SEBI regulations.
⚠️ Concerns
- The filing does not provide details on the strategic rationale or future operational plans for Bliss GVS Pharma under potential new significant ownership.
- There is no information regarding any potential counter-offers or competing bids that could influence the offer price or shareholder participation.
📅 Company Track Record
Previous filings indicated Anupam Rasayan India's offer to acquire 26.00% of Bliss GVS Pharma for ₹ 299.00 per share, with a public announcement dated May 23, 2026, and detailed public statement on May 30, 2026, published June 01, 2026. This filing represents a continuation of the open offer process.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the offer price for the Bliss GVS Pharma open offer?
The cash offer price for each equity share of Bliss GVS Pharma Limited is ₹ 299.00.
How many shares is Anupam Rasayan India Limited looking to acquire in Bliss GVS Pharma?
Anupam Rasayan India Limited intends to acquire up to 2,77,26,848 fully paid-up equity shares of Bliss GVS Pharma Limited.
What percentage of Bliss GVS Pharma's capital does this open offer represent?
The open offer represents 26.00% of Bliss GVS Pharma Limited's Expanded Voting Share Capital.
Which entity is managing the open offer for Bliss GVS Pharma?
SBI Capital Markets Ltd is serving as the Manager to the Open Offer for Bliss GVS Pharma Limited.
Questions based on this BSE filing only. For information purposes.